When managing an adult patient with moderate-to-severe atopic dermatitis who achieves only a partial clinical response on dupilumab after 6 months, how do you primarily approach treatment escalation?

In patients who partially respond to dupilumab, next steps depend on the extent of the patient's response. For patients who improve at least 50% compared to baseline, it would be reasonable to either increase dupilumab dosing frequency or add methotrexate. If much less than 50% improvement, reasonab...

Incomplete or no response to dupilumab indicates involvement of cytokines beyond IL-2.

In patients with severe, lifelong dermatitis, this could indicate microbial dysbiosis characterized by IL-17 signals. IL-2 must be blocked along with IL-17. Dual IL-17/IL-2 inhibitors are approved in other countrie...